Literature DB >> 30847669

CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.

Marco Spallazzi1, Federica Barocco2, Giovanni Michelini3, Paolo Immovilli4, Arens Taga5, Nicola Morelli4, Livia Ruffini6, Paolo Caffarra5,2.   

Abstract

Brain amyloid deposition is one of the main hallmarks of Alzheimer's disease (AD) and two approaches are available for assessing amyloid pathology in vivo: cerebrospinal fluid (CSF) biomarkers levels and amyloid load visualized by amyloid beta positron emission tomography imaging (Amy-PET) probes. We aimed to investigate the concordance between CSF biomarkers and Amy-PET in a memory clinic cohort. Moreover, using a proper clinical follow-up, we wanted to assess the diagnostic accuracy of CSF and PET biomarkers in predicting the progression of patients with mild cognitive impairment (MCI) to AD dementia. We included 31 MCI patients who underwent [18F]florbetaben PET and CSF sampling (Aβ1-42, t-Tau, p-Tau). A semiquantitative visual scan assessment was used to quantify amyloid deposition in 5 brain regions, rating from 1 (negative), to 2 and 3 (positive). CSF biomarkers were considered abnormal if: Aβ1-42 < 600 pg/ml, p-Tau/Aβ1-42 > 0.08 and t-Tau/Aβ1-42 > 0.52. We also applied less lenient cutoffs of 550 pg/ml and 450 pg/ml for Aβ1-42. The concordance rate was 77% between Amy-PET and CSF Aβ1-42 levels, and 89% between Amy-PET and p-Tau/Aβ1-42 and t-Tau/Aβ1-42. According to the clinical follow-up, Amy-PET (sensitivity [SE] 93.7%, specificity [SP] 80%) exhibited the best diagnostic accuracy in discriminating AD from non-AD, followed by p-Tau/Aβ1-42 ratio and t-Tau/Aβ1-42 ratio (SE 93.7%, SP 66.6%), and Aβ1-42 levels (SE 81%, SP 60%). The regional uptake of [18F]florbetaben PET in the precuneus and the striatum showed the best SP (86.6%). In discordant cases, the clinical diagnosis was most often in agreement with PET results. In general, concordance between CSF biomarkers and Amy-PET was good, especially when the ratios between CSF amyloid and Tau biomarkers were used. However, Amy-PET proved to be superior to CSF Aβ1-42 in terms of diagnostic accuracy for AD, with the possibility to further increase its specificity by focusing the analysis in specific areas such as the precuneus/posterior cingulate cortex and the striatum.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid PET; CSF biomarkers; MCI; Posterior cingulate cortex; Striatum

Mesh:

Substances:

Year:  2019        PMID: 30847669     DOI: 10.1007/s13760-019-01112-8

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  6 in total

Review 1.  Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease.

Authors:  Rachel F Buckley
Journal:  Neurotherapeutics       Date:  2021-03-29       Impact factor: 7.620

Review 2.  Alzheimer's disease clinical trial update 2019-2021.

Authors:  Joseph Pleen; Ryan Townley
Journal:  J Neurol       Date:  2021-10-05       Impact factor: 6.682

3.  Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly.

Authors:  Angela R Kamer; Smruti Pushalkar; Deepthi Gulivindala; Tracy Butler; Yi Li; Kumar Raghava Chowdary Annam; Lidia Glodzik; Karla V Ballman; Patricia M Corby; Kaj Blennow; Henrik Zetterberg; Deepak Saxena; Mony J de Leon
Journal:  Alzheimers Dement (Amst)       Date:  2021-04-12

4.  Evidence of plasma biomarkers indicating high risk of dementia in cognitively normal subjects.

Authors:  Ming-Chyi Pai; Chau-Chung Wu; Yi-Chou Hou; Jiann-Shing Jeng; Sung-Chun Tang; Wei-Che Lin; Cheng-Hsien Lu; Ming-Jang Chiu; Ta-Fu Chen; Sui-Hing Yan; Chaur-Jong Hu; Shieh-Yueh Yang
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

5.  Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity.

Authors:  Arianna Sala; Agneta Nordberg; Elena Rodriguez-Vieitez
Journal:  Mol Psychiatry       Date:  2020-12-11       Impact factor: 15.992

6.  Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis.

Authors:  Stefan J Teipel; Martin Dyrba; Andrea Vergallo; Simone Lista; Marie Odile Habert; Marie-Claude Potier; Foudil Lamari; Bruno Dubois; Harald Hampel; Michel J Grothe
Journal:  Front Aging Neurosci       Date:  2021-12-22       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.